30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

First Look at 2Q11 Results: NuVasive

$133MM, +11% (Biologics $24.2MM; ex-U.S. ~7.5% of revenue)
* Low single digit price pressure continues, somewhat mitigated by positive mix
* Completed launch of MaXcess 4 retractor
* Helix R Anterior Cervical Plate seeing very good early adoption
* Delays at FDA holding up commercialization of Progentix synthetic biologic, product currently
marketed ex-U.S. as AttraX, could have U.S. clearance by year-end